Hercules Capital (HTGC) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 total investment income of $125.2 million, up 7.3% year-over-year, and year-to-date investment income of $371.8 million, up 10% year-over-year.

• Net investment income for Q3 was $83.2 million ($0.51 per share), up over 8% year-over-year, with 128% coverage of the $0.40 base distribution.

• Managed assets grew to $4.6 billion, a 10.9% increase from the prior year.

• Portfolio remains diversified across technology, life sciences, and healthcare, with 97.3% of debt investments at floating rates and strong interest rate floors.

• Declared a $0.08/share supplemental distribution, marking the 17th consecutive quarter of supplemental dividends.

Financial highlights

• Q3 2024 total investment income was $125.2 million, up 7% year-over-year; net investment income was $83.2 million, up 8% year-over-year.

• Net asset value (NAV) per share was $11.40 at quarter-end, down 0.3% from Q2.

• Return on average equity (ROAE) was 18.9%; return on average assets (ROAA) was 9.5%.

• Effective portfolio yield was 14.4%; core yield was 13.3%.

• Ended Q3 with $572.3 million in liquidity and a weighted average cost of debt at 5.1%.

Outlook and guidance

• Expect Q4 core yield between 13%-13.3%, with prepayments forecasted at $150 million-$250 million.

• Pending commitments of $630 million in signed non-binding term sheets as of October 25, 2024.

• Management expects continued portfolio growth, with $489 million in unfunded commitments and $180.5 million in non-binding term sheets outstanding.

• SG&A expenses for Q4 expected at $22 million-$23 million, with RIA expense allocation of ~$2.7 million.

• Optimistic about delivering another record year of new gross fundings for FY 2024.